Group 1: ProKidney Corp. (PROK) - ProKidney is a clinical-stage biotechnology company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 5.8% over the last 60 days [1] - ProKidney's shares gained 371.7% over the last three months, significantly outperforming the S&P 500's advance of 18.2% [1] - The company has a Momentum Score of A [1] Group 2: Roku, Inc. (ROKU) - Roku operates a TV streaming platform and holds a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 5.3% over the last 60 days [2] - Roku's shares gained 55.4% over the last three months, also outperforming the S&P 500's advance of 18.2% [2] - The company has a Momentum Score of B [2] Group 3: Pharming Group N.V. (PHAR) - Pharming is a biopharmaceutical company with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings increased nearly 7% over the last 60 days [3] - Pharming's shares gained 26.6% over the last three months, again outperforming the S&P 500's advance of 18.2% [3] - The company has a Momentum Score of B [3]

Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases [5] - The company is involved in the commercialization and development of a portfolio of innovative medicines, including small molecules and biologics [5] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [5] Upcoming Financial Results - Pharming will report its preliminary (unaudited) financial results for the second quarter and first half of 2025 on July 31, 2025 [1] - A business update will also be provided during the same announcement [1] - Management will host a conference call and webcast for analysts and investors at 13:30 CEST/07:30 am EDT on the same day [1]

Pharming Group N.V. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39822 (Exact Name of Registrant as Specified in Its Charter) Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Fo ...

Core Insights - Pharming Group N.V. is presenting Phase III clinical data for leniolisib, targeting pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) at the 2025 Annual Meeting of the Clinical Immunology Society [1][2] Presentations - The presentation titled "Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment With PI3Kδ Inhibitor Leniolisib in Pediatric Patients Aged 4-11 Years With Activated PI3Kδ Syndrome (APDS)" will be led by Dr. Shanmuganathan Chandrakasan on May 2, 2025 [2] - Additional presentations include a systematic literature review on immune dysregulation in common variable immunodeficiency and insights into APDS from patient perspectives [2] About Leniolisib - Leniolisib is an oral small molecule PI3Kδ inhibitor approved in several countries as the first targeted treatment for APDS in patients aged 12 and older [3] - The drug has shown statistically significant improvement in co-primary endpoints in a Phase III clinical trial, indicating a favorable impact on immune dysregulation [3] - Leniolisib is under regulatory review in the European Economic Area, Canada, and other regions, with plans for approval in Japan [3] About Pharming Group N.V. - Pharming Group N.V. is a global biopharmaceutical company focused on developing innovative medicines for rare and life-threatening diseases [4] - The company is headquartered in Leiden, the Netherlands, and operates in over 30 markets worldwide [4]

Core Viewpoint - Pharming Group N.V. has received positive final guidance from the National Institute for Health and Care Excellence (NICE) for the reimbursement and use of Joenja® (leniolisib) in treating activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older within the NHS in England and Wales [1][2][4] Group 1: NICE Recommendation and Clinical Data - The NICE recommendation is based on comprehensive data from a Phase III clinical trial that showed significant improvements in immune deficiency and dysregulation with leniolisib compared to placebo [2][4] - The Phase III trial results indicated sustained clinical improvements during long-term treatment in an open-label extension trial [2] Group 2: Impact on Patients and Healthcare - The NICE recommendation is viewed as a significant milestone for patients with APDS, enhancing treatment options and potentially improving their quality of life [3][4] - Joenja® is now available for use and funded in England through the Innovative Medicines Fund, with expected funding in Wales within three months [4] Group 3: About Joenja® and APDS - Joenja® is the first and only targeted treatment for APDS, an oral small molecule PI3Kδ inhibitor that addresses the underlying immune system issues associated with the condition [8] - APDS is a rare primary immunodeficiency affecting approximately 1 to 2 people per million worldwide, characterized by severe recurrent infections and immune dysregulation [6][7]

[Form 6-K Report of Foreign Private Issuer (April 2025)](index=1&type=section&id=Form%206-K%20Report%20of%20Foreign%20Private%20Issuer%20(April%202025)) This Form 6-K report provides key announcements from a foreign private issuer in April 2025 [Announcement of 2024 Annual Report and Form 20-F Filing](index=3&type=section&id=Pharming%20Group%20announces%20the%20filing%20of%20its%202024%20Annual%20Report%20and%20Form%2020-F) Pharming Group N.V. announced the filing of its Annual Report for the year ended December 31, 2024, along with its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) - Pharming Group N.V. has filed its Annual Report for the year ended December 31, 2024[8](index=8&type=chunk) - The company also filed its Annual Report on Form 20-F with the U.S. SEC for the same period[9](index=9&type=chunk) - The reports are available on the Pharming.com website under the 'Investors' section and through the SEC website[8](index=8&type=chunk)[9](index=9&type=chunk) [About Pharming Group N.V.](index=3&type=section&id=About%20Pharming%20Group%20N.V.) Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands, focusing on innovative medicines for rare and life-threatening diseases across over 30 markets - Pharming is a global biopharmaceutical company dedicated to treating patients with rare, debilitating, and life-threatening diseases[10](index=10&type=chunk) - The company's portfolio includes commercialized and developing innovative medicines, such as small molecules and biologics[10](index=10&type=chunk) - Headquartered in Leiden, the Netherlands, Pharming serves patients in over 30 markets worldwide[10](index=10&type=chunk) [Other Information](index=3&type=section&id=Other%20Information) This section discloses that the press release content may qualify as inside information under EU Market Abuse Regulation and provides contact details for investor and public relations - The press release may contain information that qualifies as 'inside information' within the meaning of Article 7(1) of the EU Market Abuse Regulation[12](index=12&type=chunk) - Contact details for investor relations, corporate communications, and public relations are provided for further inquiries[13](index=13&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Core Insights - Pharming Group N.V. has initiated a Phase II clinical trial for leniolisib targeting common variable immunodeficiency (CVID) patients with immune dysregulation, marking a significant step in addressing unmet medical needs in this patient population [1][4]. Group 1: Clinical Trial Details - The Phase II trial is a single-arm, open-label study involving approximately 20 patients aged 12 and older, focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of leniolisib in CVID patients [2]. - The trial specifically targets CVID patients exhibiting lymphoproliferation and at least one additional clinical manifestation of immune dysregulation, such as interstitial lung disease or autoimmune cytopenias [2][3]. - The lead investigator is Dr. Jocelyn Farmer, with clinical sites located in the US, UK, and EU [2]. Group 2: Disease Context and Unmet Needs - CVID is the largest group of symptomatic primary immunodeficiency patients, with about 50% experiencing autoimmune and lymphoproliferative complications due to immune dysregulation [3]. - Patients with CVID and immune dysregulation have an 11-fold increased mortality rate compared to those with infectious manifestations alone, highlighting the critical need for effective therapies [3]. - The global prevalence of CVID with immune dysregulation is estimated at approximately 39 patients per million [3]. Group 3: Leniolisib Overview - Leniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, currently approved in the U.S. for treating activated phosphoinositide 3-kinase delta syndrome (APDS) [5][6]. - The drug has shown statistically significant improvement in clinical trials for APDS, and its safety and tolerability for long-term use have been supported by interim data [6]. - Leniolisib is under regulatory review in multiple regions, including the European Economic Area, Canada, and Australia, with plans for further approvals in Japan and South Korea [6]. Group 4: Company Background - Pharming Group N.V. is a global biopharmaceutical company focused on developing therapies for rare and life-threatening diseases, with a portfolio that includes protein replacement therapies and precision medicines [7]. - The company is headquartered in Leiden, the Netherlands, and operates in over 30 markets worldwide [7].

Financial Data and Key Metrics Changes - Full-year 2024 revenues increased by 21% to $297 million, exceeding guidance, with strong performance in Q4 [7][42] - Operating profit increased by $5.6 million, marking the second consecutive quarter of positive operating profit [43] - Net results shifted from a loss in Q4 2023 to a net profit in Q4 2024, with positive operating cash flow for the second quarter in a row [44] Business Line Data and Key Metrics Changes - RUCONEST revenue grew 11% to $252 million for the year, with a 9% increase in Q4, driven by new patient enrollments and prescriber base expansion [7][11] - Joenja revenue surged by 147% to $45 million in 2024, with a 65% increase in Q4 [9][12] Market Data and Key Metrics Changes - The prescriber base for RUCONEST increased by 11% and new patient enrollments rose by 24% [11] - Joenja's patient pipeline is expanding, with over 240 identified patients in the US, 40% of whom are on paid therapy [20] Company Strategy and Development Direction - The company aims to develop a leading global rare disease portfolio, leveraging a proven clinical development and commercial infrastructure [7] - The acquisition of Abliva is seen as a strategic move to enhance the company's pipeline and revenue potential [6][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in RUCONEST's continued growth despite increasing competition, citing its unique profile and strong patient experience [50][79] - The company anticipates total revenues for 2025 to be between $315 million and $335 million, reflecting continued growth in RUCONEST and Joenja [47] Other Important Information - The company is actively monitoring potential US tariffs on drugs and is taking steps to mitigate any impact on its supply chain [70] - The anticipated operating expenses related to the Abliva acquisition are estimated at $30 million for 2025, including $17 million for R&D [49][69] Q&A Session Summary Question: Insights on KL1333 and patient population - The addressable population for KL1333 is estimated at 30,000 patients in the US and Europe, focusing on those with specific mitochondrial DNA mutations [59] Question: Breakdown of patients in the expanded access program - Patients in the expanded access program are in multiple countries, with some on paid therapy through name patient programs, but specific numbers are not disclosed [63] Question: Recurring costs from Abliva acquisition - Of the $30 million anticipated OpEx from the Abliva acquisition, approximately $17 million will be for R&D, with the remainder being non-recurring costs [69] Question: Impact of potential US tariffs - The company is monitoring the situation regarding US tariffs and is exploring ways to minimize potential impacts on its supply chain [70] Question: RUCONEST's growth despite competition - Management believes RUCONEST will remain a treatment of choice due to its unique profile and strong patient experience, supported by market research [79][81] Question: Timeline for CVID trials - A Phase 2 study is anticipated for CVID, with a Phase 3 study likely required for registration [102] Question: Future expectations for CVID and fast-track designation - The company plans to explore fast-track designation options for CVID, given the severity of the disease [105]

Financial Performance - Total revenues for 2024 increased by 21% to US$297.2 million, exceeding guidance of US$280-$295 million, driven by record RUCONEST® revenue and strong Joenja® growth [3][8][52] - RUCONEST® revenue for the full year 2024 was US$252.2 million, an 11% increase compared to 2023, while Joenja® revenue reached US$45.0 million, a 147% increase in its first full year of sales [8][52] - Fourth quarter 2024 total revenues increased by 14% to US$92.7 million compared to the same quarter in 2023, with RUCONEST® revenue at US$79.6 million (9% increase) and Joenja® revenue at US$13.1 million (66% increase) [8][44][49] Clinical Development and Pipeline - The company is advancing regulatory reviews for leniolisib in key markets and for pediatric use, with two ongoing Phase II trials for additional primary immunodeficiencies (PIDs) [4][27] - The acquisition of Abliva has been completed, adding KL1333 for mitochondrial diseases to the clinical pipeline, which has blockbuster potential [5][34] - Positive top-line results were announced for a Phase III trial of leniolisib in children aged 4 to 11, with global regulatory filings planned for the second half of 2025 [21][19] Market and Product Insights - The U.S. market contributed 98% of 2024 revenues, with the company focusing on expanding its portfolio in the U.S. and Joenja® in key countries [10][8] - The company identified over 880 diagnosed APDS patients globally, with ongoing initiatives to diagnose additional patients through genetic testing programs [14][15] - The strong growth in RUCONEST® revenue is attributed to new physician prescriptions and patient enrollments, with a 24% increase in total enrollments in 2024 [11][9] Financial Outlook - For 2025, the company anticipates total revenues between US$315 million and US$335 million, representing a growth of 6% to 13% [78] - The company plans to continue investing in its product portfolio and R&D pipeline, particularly for PIDs and primary mitochondrial diseases [7][78] - Operating expenses are expected to remain below the prior year's levels, with an estimated US$30 million in Abliva-related expenses [78]